Daiichi Sankyo Inc. — Sponsor Intelligence | 47 EU Trials

Filter these 47 trials by condition, phase, country and more.

Open in Search →

47 Registered trials

21 Recruiting

23 Completed trials

20 Countries active

38 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase III: 16 Phase II/III: 2 Phase II: 7 Phase I/II: 5 Phase I: 5 Phase I (Other): 6 Phase I (FiH): 2 Other: 4

Oversight events:

2 serious breaches 14 temporary halts 4 urgent safety measures 1 corrective measure across 7 trials

View oversight register →

100%

23 of 23 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 8 Ovarian cancer 5 Breast cancer metastatic 4 HER2 positive breast cancer 4 Endometrial cancer 3 Non-small cell lung cancer metastatic 3 Colorectal cancer 3 Neoplasm 2 HER2 positive gastric cancer 2 Metastatic gastric cancer 2 Breast cancer 2 Small cell lung cancer extensive stage 2

Top IMPs

TRASTUZUMAB DERUXTECAN 10 DATOPOTAMAB DERUXTECAN 6 IFINATAMAB DERUXTECAN 5 PEMBROLIZUMAB 4 CISPLATIN 3 PATRITUMAB DERUXTECAN 3 VALEMETOSTAT TOSILATE 3 CARBOPLATIN 2 QUIZARTINIB DIHYDROCHLORIDE 2 RALUDOTATUG DERUXTECAN 2 TRASTUZUMAB EMTANSINE 2 BEVACIZUMAB 1

All trials — page 2

47 total

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Phase III 13 countries DATOPOTAMAB DERUXTECAN; PEMBROLIZUMAB
I-DXd in Patients With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Ended

2024-512368-79-00 Phase II 3 countries IFINATAMAB DERUXTECAN
Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF… Ended

2023-507964-38-00 Phase III 10 countries PATRITUMAB DERUXTECAN
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended

2023-507933-12-00 Phase III 12 countries DATOPOTAMAB DERUXTECAN; PEMBROLIZUMAB
Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma Ended

2023-507381-13-00 Phase II 3 countries VALEMETOSTAT TOSILATE
Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or A… Ended

2023-507963-20-00 Phase III 10 countries RAMUCIRUMAB; TRASTUZUMAB DERUXTECAN
DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Ended

2023-509865-19-00 Phase III 7 countries DATOPOTAMAB DERUXTECAN
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 Phase III 13 countries TRASTUZUMAB DERUXTECAN; TRASTUZUMAB EMTANSINE
Patritumab Deruxtecan in Subjects with Metastatic or Locally Advanced EGFR-mutated NSCLC Ended

2024-512238-13-00 Phase II 6 countries PATRITUMAB DERUXTECAN
Study of U3-1402 in subjects with non-small cell lung cancer Ended

2024-511205-33-00 Phase I (Other) 2 countries
Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Ended

2024-511204-16-00 Phase III 4 countries TRASTUZUMAB DERUXTECAN; TRASTUZUMAB EMTANSINE
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood Ended

2023-510009-16-00 Phase I/II 7 countries QUIZARTINIB DIHYDROCHLORIDE
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors Halted

2024-516916-93-00 Phase I (Other) 3 countries DATOPOTAMAB DERUXTECAN; TRASTUZUMAB DERUXTECAN; VALEMETOSTAT TOSILATE
Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin. Ended

2024-519851-27-00 1 country
Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin. Ended

2024-519849-29-00 1 country
Evaluating Bioequivalence of a Fixed Dose Combination versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin. Ended

2024-519852-10-00 1 country
Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin. Ended

2024-519850-35-00 1 country
An early-stage clinical study of a potential new medicine for patients with Netherton Syndrome Ended

2022-502853-32-00 Phase I/II 1 country DS-2325A
Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell … Ended

2023-508003-20-00 Phase I (Other) 2 countries
Phase 2 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations Ended

2024-511449-21-00 Phase II 3 countries DATOPOTAMAB DERUXTECAN
Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Ended

2023-509866-39-00 Phase I (Other) 2 countries
First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors Ended

2024-517984-21-00 Phase I 3 countries
A Study of Valemetostat Tosylate Plus Pembrolizumab versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations Ended

2024-519671-26-00 Phase I/II 3 countries PEMBROLIZUMAB; VALEMETOSTAT TOSILATE

Showing 25–47 of 47 trials

← All sponsors A–Z